Copenhagen, Denmark—A year of sunitinib therapy after nephrectomy increases disease-free survival (DFS) by more than one year in patients who have undergone nephrectomy for locoregional clear cell renal cell carcinoma (RCC), according to a Phase III trial. The trial, limited to patients with a high risk for recurrence, was characterized as the first to show a benefit for an adjuvant therapy in RCC.
“These results represent a major step forward in the clinical management of renal